Table 2.
Subject | Total sequences in PB | Total sequences in CSF | Number of shared clones CSF (n/total) | Shared sequences (% CSF repertoire) | Clone V‐CDR3‐J |
---|---|---|---|---|---|
MS‐1 | 72,414 | 1,757,415 | 0/105 | 0% | – |
MS‐2 | 342,597 | 700,041 | 4/43 | 0.1% |
V7.2‐CASSPGYSGYEQYF‐J2.7 V7.6‐CASSLEPGRNEKLF‐J1.4 V7.2‐CASSLGGGISYEQYF‐J2.7 V7.2‐CASSPLAGGTYNEQF‐J2.1 |
MS‐3 | 51,234 | 4,036,432 | 1/185 | 2.59% | V4.1‐CASSQDRYRQNTEAF‐J1.1 |
MS‐4 | 244,397 | 2,202,176 | 0/75 | 0% | – |
MS‐5a | 9,631,112 | 11,386 | – | – | – |
IIH‐1 | 834,970 | 985,623 | 1/20 | 3.7% | V12.3‐CASQQGSGSYEQYF‐J2.7 |
IIH‐2 | 399,951 | 3,085,051 | 0/24 | 0% | – |
IIH‐3 | 294,631 | 553,871 | 0/19 | 0% | – |
IIH‐4 | 2,737,399 | 914,804 | 0/22 | 0% | – |
IIH‐5 | 336,773 | 3,694,466 | 1/109 | 9.2% | V7.2‐CASSLGAGGSTQYF‐J2.3 |
PB, peripheral blood.
Subject MS‐5 had one T‐cell clonotype classified as hyperexpanded in the CSF compartment.